Total Equity Funding
$32.27M in 4 Rounds from 7 Investors
Most Recent Funding
$7.62M Series C on October 25, 2016
Vienna, Wien
Miracor Medical Systems GmbH is an Austrian medical device company developing disruptive solutions to treat severe heart diseases.
Medical Device, Health Care, Health Diagnostics

Company Details


Miracor Medical Systems GmbH is an Austrian medical device company developing disruptive solutions to treat severe heart diseases; striving to bring back cardiac patients to normal life.

The company was founded in May 2008 by Professor Dr. Dr. Werner Mohl and the European venture capital firms Earlybird and Delta Partners.

Miracor develops and commercializes the PiCSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System, a technology platform designed to improve clinical outcome of patients with impaired cardiac function.

PiCSO AMI Therapy seeks to increase blood flow to the affected heart tissue, thereby improving the overall heart function after an Acute Myocardial Infarction (AMI). Recent Pre-Clinical and Clinical Studies have successfully demonstrated the positive effects of PiCSO on myocardial function and infarct size in acute heart attack patients. The CE-marked PiCSO AMI Impulse System consists of a driving console and associated catheters and offers the Heart Team new options to improve clinical outcome in Acute Myocardial Infarction patients.

The company is conducting further post-market clinical trials to further proof the safety and effectiveness of the PiCSO Therapy in heart attack patients undergoing coronary revascularization with percutaneous coronary intervention (PCI-stenting).

First clinical studies showed that also Heart Failure (HF) patients may benefit from even only short periods of PiCSO by improving structural integrity and induction of regenerative pulses. Based on this, further research activities are currently conducted for the treatment of Heart Failure patients, aiming to reverse the adverse mechanisms of the failing heart with the PiCSO HF Therapy.

Funding Rounds (5) - $35.77M

DateAmount / RoundValuationLead InvestorInvestors
Oct, 2016€7M / Series C1
Jan, 2015€4.5M / Series B5
Feb, 2012$3.5M / Grant1
Oct, 2011$10M / Series B4
May, 2008€6M / Series A2

Current Team (4)


Products (1)

  • PiCSO Therapy aims to improve myocardial perfusion and cardiac function in patients with myocardial infarction.

Offices/Locations (2)

  • Headquarters

    Gumpendorferstrasse 139

    Top 1.05

    Vienna, Wien 1060


  • Miracor UK Limited

    Manchester Science Park

    Pencroft Way

    Manchester, Manchester M15 6JJ

    United Kingdom

Images (2)


Add Acquisitions

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos